Intermittent Fasting to Improve Insulin Secretion

Summary

Type 2 diabetes (T2D) mellitus is a challenge for health care systems as the numbers increases constantly. In 2014, 422 million people had been living with diabetes worldwide. The absolute numbers of people with prediabetes have also grown substantially over 25 years worldwide. In Germany, about 10% of the population has T2D and another 21 % of the population has prediabetes.Overall, 16% of all deaths in Germany are attributable to type 2 diabetes. Macro- and microvascular complications of diabetes imply a significant threat for the patients and are already present in the prediabetic state. Short term and long term complications, the burden of treatment, and reduced quality of life are major burdens of the disease. Accumulating data indicate that currently recommended therapeutic diet regimens in patients with obesity and diabetes are not sustainable on the long term. Novel concepts are therefore urgently needed.

T2D occurs when insulin secretion from pancreatic beta-cells cannot sufficiently be increased to compensate for insulin resistance. Causes of beta-cell dysfunction are heterogeneous. In addition, the most important determinants of diabetes remission are the extend of weight loss and restoration of beta-cell function. In the course of diabetes progression, the inability to recover insulin secretion might identify the state of no return to normal glucose tolerance. It is therefore crucial to improve insulin secretion in treatment and prevention of diabetes. Up to now lifestyle intervention trials in prediabetes or pharmacological intervention trials in diabetes did not show improvement of insulin secretion after intervention. However, one recent small human trial shows that intermittent fasting (early time restricted fasting) is able to improve insulin secretion.Currently, there are no trials that examine the effect of intermittent fasting in individuals with a broad range of impaired glucose metabolism (from prediabetes to diabetes). Recently novel subtypes of diabetes and prediabetes with high risk for the early manifestation of diabetes complications have been identified. Currently, prevention strategies for this high risk individuals have not been examined yet. We will study for the first time the effectiveness of 4 weeks intermittent fasting on changes in insulin secretion capacity in subphenotypes of diabetes and in prediabetes.

Conditions

• PreDiabetes
• Diabetes type2
• Intermittent Fasting
• Insulin Secretion

Interventions

BEHAVIORAL

Intermittent fasting

The intermittent fasting intervention consists of a decreased daily caloric intake of 400 kcal below individual requirements (Harris Benedict Formula) combined with early time restricted fasting according to the schema 16:8. fasting will be performed over 4 weeks.

BEHAVIORAL

Control diet

Control group will be advised to reduce daily caloric intake of 400 kcal below individual requirements (Harris Benedict formula)

Sponsors & Collaborators

• German Institute of Human Nutrition

  collaborator OTHER

• Charite University, Berlin, Germany

  collaborator OTHER

• University Hospital Carl Gustav Carus

  collaborator OTHER

• University of Leipzig

  collaborator OTHER

• Ludwig-Maximilians - University of Munich

  collaborator OTHER

• University Hospital Heidelberg

  collaborator OTHER

• University of Luebeck

  collaborator OTHER

• German Diabetes-Center, Leibniz-Institut in Düsseldorf

  collaborator OTHER

• German Center for Diabetes Research

  collaborator OTHER

• University Hospital Tuebingen

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-04-08

Primary Completion

2026-12-31

Completion

2027-03-01

Countries

• Germany

Study Locations